Alphamab Oncology
Signal active
Investment Firm
Overview
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment with multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and they are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.
Highlights
Founded
2009
Industry
Biotechnology
Employees
251-500
Investment
2
Lead Investment
0
Exits
undefined
Stages
Seed
Investor Type
N/A
Location
Asia
Contact Information
Social
Profile Resume
Alphamab Oncology, established in 2009 and headquartered in Asia., specializes in Seed investments across 3D Technology, Biotechnology, Medical, Medical Device, Manufacturing, Financial Services, Finance, Venture Capital, Business Development, Enterprise. Their recent investments include Sidi Diagnostics, Simcere Pharma, China Minsheng Investment Group, Lucion, Spinnotec. The highest investment round they participated in was $3.1B. Among their most notable exits are Sidi Diagnostics and Simcere Pharma. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Alphamab Oncology has made 2 investments. Their most recent investment was on Mar 01, 2020, when Sidi Diagnostics raised $40.0M.
investments
2
Diversity investments
0
Lead investments
0
Number of exits
undefined
Investments
2
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Mar 21, 2016 | SmartNuclide | Biotechnology | 462.9K |
| Mar 01, 2020 | Sidi Diagnostics | 3D Technology | 40.0M |
Exits
0
Funding Timeline
Funding rounds
2
Investors
8
Funds
0
Funding Rounds
2
Alphamab Oncology has raised 2 rounds. Their latest funding was raised on Mar 01, 2020 from a Venture Round - Sidi Diagnostics round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Mar 21, 2016 | Angel Round - SmartNuclide | - | 462.9K | - |
| Mar 01, 2020 | Venture Round - Sidi Diagnostics | - | 40.0M | - |
Investors
10
Alphamab Oncology is funded by 10 investor(s). PAG and Hudson Bay Capital Management Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
China Venture Capital | No | Series B - Alphamab Oncology | 60.0M |
Advantech Capital | No | Series B - Alphamab Oncology | 60.0M |
Hudson Bay Capital Management | Yes | Series B - Alphamab Oncology | 60.0M |
PAG | No | Series B - Alphamab Oncology | 60.0M |
PAGFund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.